Table 3 –
Drugs | % HDL-C Elevation | Mechanism of Action | Stage of Development |
---|---|---|---|
Niacin | 30-50 | Multifactorial effects | Approved |
Fibrates (Fenofibrate) |
5-15 | Multifactorial effects by acting as PPAR agonists | Approved |
CETP- Inhibitors (Anacetrapib, Dalcetrapib) |
25-135 | Inhibit transfer of cholesteryl esters away from HDL | Phase III (completed) |
BET Inhibitor (Apabetalone) |
5-10 | Epigenetic modification altering apoA-I transcription | Phase III (completed) |
HDL Infusion Therapy (CSL-112) |
50-200 | Direct infusion of exogenous HDL | Ongoing Phase III (AEGIS-II: NCT03473223) |
Recombinant LCAT (MEDI6012) |
50-100 | Increase esterification of cholesterol on HDL | Ongoing Phase II ((REAL-TIMI 63B: NCT03578809)) |
HDL=high density lipoprotein; PPAR=peroxisome proliferator-activated receptor; CETP=cholesteryl ester transfer protein; BET=bromodomain and extraterminal; apoA-I=apolipoprotein A-I; AEGIS=ApoA-I Event reducing in Ischemic Syndromes; LCAT=lecithin-cholesterol acyltransferase;